Inviragen and the International Vaccine Institute Expand Partnership

FORT COLLINS, Colo.–(BUSINESS WIRE)– Under its existing Memorandum
of Understanding, Inviragen and the International Vaccine Institute (IVI)
announced a collaboration to assess the total health burden of dengue cases in
Colombia and Thailand. The Mahidol University Department of Tropical
Pediatrics in Thailand and PECET (Programa de Estudio y Control de
Enfermedades Tropicales) at Universidad de Antioquia in Medellin, Colombia
will manage the studies, which aim to detail the burden of dengue disease from
epidemiological, economic, behavioral and market-demand perspectives.

Inviragen and the International Vaccine Institute Expand Partnership Read More »

Smaato expands mobile advertising opportunities for app developers by supporting Windows Phone 8

Build Conference, Redmond, Washington – Smaato, the leading mobile ad monetization
platform for fast-growing application developers, today announced the release of the
Smaato’s advertising SDK for Windows Phone 8 to support Microsoft’s launch of its
Windows Phone 8 Software Development Kit (SDK).

Smaato expands mobile advertising opportunities for app developers by supporting Windows Phone 8 Read More »

MerLion Announces Successful Completion of a Phase I Clinical Study with Intravenously Administered Finafloxacin

Singapore, 7th November, 2012 – Following successful first-in-man Phase I and two
Phase IIa clinical studies with the oral formulation of finafloxacin, MerLion
Pharmaceuticals Pte Ltd (MerLion) announces the completion of the first Phase I
study using an intravenous (iv) formulation of this highly differentiated antibacterial
candidate.

MerLion Announces Successful Completion of a Phase I Clinical Study with Intravenously Administered Finafloxacin Read More »

S*BIO Initiate Global P3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of MF

SINGAPORE, Oct. 25, 2011 – S*BIO Pte Ltd today announced plans to initiate a global Phase 3
clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further
demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is
actively exploring partnering opportunities for the advancement of its leading JAK2 program.

S*BIO Initiate Global P3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of MF Read More »

Ooyala completes Series E funding with investment firm EDBI,establishes APAC Digital Broadcast Operations Hub in Singapore

MOUNTAIN VIEW, CALIF. and SINGAPORE (October 2, 2012) – Ooyala today
announced that Singapore-based global investment firm EDBI has joined Telstra and others as
Ooyala investors in closing its Series E round of funding. Telstra, one of the largest
multinational telecommunications companies in the world and Australia’s largest service
provider, led the round. The total amount raised is $35 million. To further fuel its momentum
throughout Asia, Ooyala is also establishing a new hub in Singapore to house its regional digital
broadcasting operations and services.

Ooyala completes Series E funding with investment firm EDBI,establishes APAC Digital Broadcast Operations Hub in Singapore Read More »

Crisp Media Launches Objectives-Driven, Branded Mobile Ad Products Proprietary Suite of Ad Products

NEW YORK, Sep 25, 2012 (BUSINESS WIRE) — Crisp Media, the leader in delivering rich
media-based, digital display advertising to mobile devices, today announced the launch
of its first-to-market suite of ad products designed to successfully achieve commonly
requested advertiser objectives. The products were conceived and developed using the
very best practices in mobile advertising executions to help advertisers, agencies and
publishers to quickly develop and deploy powerful mobile ad units, and to effectively
measure their success against campaign goals

Crisp Media Launches Objectives-Driven, Branded Mobile Ad Products Proprietary Suite of Ad Products Read More »